Tyrosine kinase inhibitor-induced hypothyroidism: Incidence, etiology, and management

Targeted Oncology

Volumn 6, Issue 4, 2011, Pages 217-226

  Brown, Rebecca L ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Hypothyroidism; Sunitinib; Tyrosine kinase inhibitor

Indexed keywords

ALPHA INTERFERON; AXITINIB; CYTOKINE; DASATINIB; IMATINIB; LEVOTHYROXINE; MOTESANIB; NILOTINIB; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROPYLTHIOURACIL; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TAMOXIFEN; THYROID HORMONE; THYROID PEROXIDASE; THYROTROPIN; VANDETANIB; VASCULOTROPIN RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANASARCA; BLOOD TOXICITY; BODY TEMPERATURE DISORDER; BREAST CANCER; CHRONIC MYELOID LEUKEMIA; COLD INTOLERANCE; COLORECTAL CANCER; CONFUSION; CONSTIPATION; DERMATOFIBROSARCOMA PROTUBERANS; DIARRHEA; DIFFERENTIATED THYROID CANCER; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GLIOMA; HEART PALPITATION; HEAT INTOLERANCE; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; HYPERTHYROIDISM; HYPOTHYROIDISM; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG CANCER; MELANOMA; MULTIPLE CYCLE TREATMENT; NECK PAIN; NONHUMAN; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; REVIEW; SIDE EFFECT; SOLID TUMOR; THYROID CANCER; THYROID DISEASE; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY; THYROIDITIS; THYROTROPIN BLOOD LEVEL;

ANGIOGENESIS INHIBITORS; ANIMALS; HUMANS; HYPOTHYROIDISM; INCIDENCE; INDOLES; PROTEIN KINASE INHIBITORS; PYRROLES;

EID: 84856071108     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-011-0197-2     Document Type: Review

References (53)

1. Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, Reddy S, Dreicer R, Bukowski RM (2007) Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 99:81-83
2. Wong E, Rosen LS, Mulay M, Vanvugt A, Dinolfo M, Tomoda C, Sugawara M, Hershman JM (2007) Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 17:351-355 (Pubitemid 46776140)
3. Schoeffski P WP, Himpe U, Dychter SS, Baum CM, Prenen H, Wildiers H, Bex M, Dumez H, (2006). Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I Vol 24, No 18S (June 20 Supplement), 2006:3092
4. Desai J, Yassa L, Marqusee E, George S, Frates MC, Chen MH, Morgan JA, Dychter SS, Larsen PR, Demetri GD, Alexander EK (2006) Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 145:660-664 (Pubitemid 46768841)
5. Mannavola D, Coco P, Vannucchi G, Bertuelli R, Carletto M, Casali PG, Beck-Peccoz P, Fugazzola L (2007) A novel tyrosinekinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab 92:3531-3534 (Pubitemid 47435331)
6. Wolter P, Stefan C, Decallonne B, Dumez H, Bex M, Carmeliet P, Schoffski P (2008) The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br J Cancer 99:448-454
7. Tamaskar I, Bukowski R, Elson P, Ioachimescu AG, Wood L, Dreicer R, Mekhail T, Garcia J, Rini BI (2008) Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Ann Oncol 19:265-268 (Pubitemid 351201706)
8. Clement P WP, Stefan C, Decallonne B, Dumez H, Wildiers H, Schöffski P (2008) J Clin Oncol 26 (May 20 suppl; abstr 16145)
9. de Groot JW, Zonnenberg BA, van Ufford-Mannesse PQ, de Vries MM, Links TP, Lips CJ, Voest EE (2007) A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab 92:3466-3469 (Pubitemid 47435321)
10. de Groot JW, Zonnenberg BA, Plukker JT, van Der Graaf WT, Links TP (2005) Imatinib induces hypothyroidism in patients receiving levothyroxine. Clin Pharmacol Ther 78:433-438 (Pubitemid 41393678)
11. Dora JM, Leie MA, Netto B, Fogliatto LM, Silla L, Torres F, Maia AL (2008) Lack of imatinib-induced thyroid dysfunction in a cohort of non-thyroidectomized patients. Eur J Endocrinol 158:771-772 (Pubitemid 351639617)
12. Weisberg E, Catley L, Wright RD, Moreno D, Banerji L, Ray A, Manley PW, Mestan J, Fabbro D, Jiang J, Hall-Meyers E, Callahan L, DellaGatta JL, Kung AL, Griffin JD (2007) Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood 109:2112-2120 (Pubitemid 46348213)
13. Manley PW, Drueckes P, Fendrich G, Furet P, Liebetanz J, Martiny-Baron G, Mestan J, Trappe J, Wartmann M, Fabbro D (2010) Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta 1804:445-453
14. Kim TD, Schwarz M, Nogai H, Grille P, Westermann J, Plockinger U, Braun D, Schweizer U, Arnold R, Dorken B, le Coutre P (2010) Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosomepositive chronic myeloid leukemia. Thyroid 20:1209-1214
15. Yoshizato T, Nannya Y, Yoshiki Y, Nakamura F, Imai Y, Ichikawa M, Kurokawa M (2011) Nilotinib-induced hypothyroidism in a patient with chronic myeloid leukemia. Int J Hematol 93:400-402
16. Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Schlumberger MJ (2008) Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 359:31-42 (Pubitemid 351931094)
17. Wells SA, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Vasselli JR, Read J, Schlumberger M (2010) Vandetanib (VAN) in locally advanced or metastatic medullary thyroid cancer (MTC): a randomized, double-blind phase III trial (ZETA). J Clin Oncol 28 (Suppl; abstr 5503)
18. Robinson BG, Paz-Ares L, Krebs A, Vasselli J, Haddad R (2010) Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 95:2664-2671
19. Kelly RJ, Rixe O (2010) Axitinib (AG-013736). Recent Results Cancer Res 184:33-44
20. Fujiwara Y, Kiyota N, Chayahara N, Suzuki A, Umeyama Y, Mukohara T, Minami H (2011) Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients. Investig New Drugs. doi:10.1007/s10637-011-9637- 1
21. Wolter P SC, Decallonne B, Dumez H, Fieuws S, Wildiers H, Clement P, Debaere D, Van Oosterom A, and Schoffski P (2008) Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of sunitinib in patients (pts) with advanced renal cell cancer (RCC). J Clin Oncol 26 (May 20 suppl; abstr 16145)
22. Sato S, Muraishi K, Tani J, Sasaki Y, Tokubuchi I, Tajiri Y, Yamada K, Suekane S, Miyajima J, Matsuoka K, Hiromatsu Y (2010) Clinical characteristics of thyroid abnormalities induced by sunitinib treatment in Japanese patients with renal cell carcinoma. Endocr J 57:873-880
23. Grossmann M, Premaratne E, Desai J, Davis ID (2008) Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. Clin Endocrinol (Oxf) 69:669-672
24. Sakurai K, Fukazawa H, Arihara Z, Yoshida K (2010) Sunitinib-induced thyrotoxicosis followed by persistent hypothyroidism with shrinkage of thyroid volume. Tohoku J Exp Med 222:39-44
25. Rogiers A, Wolter P, Op de Beeck K, Thijs M, Decallonne B, Schoffski P (2010) Shrinkage of thyroid volume in sunitinib-treated patients with renal-cell carcinoma: a potential marker of irreversible thyroid dysfunction? Thyroid 20:317-322
26. Viglietto G, Romano A, Manzo G, Chiappetta G, Paoletti I, Califano D, Galati MG, Mauriello V, Bruni P, Lago CT, Fusco A, Persico MG (1997) Upregulation of the angiogenic factors PlGF, VEGF and their receptors (Flt-1, Flk-1/KDR) by TSH in cultured thyrocytes and in the thyroid gland of thiouracil-fed rats suggest a TSH-dependent paracrine mechanism for goiter hypervascularization. Oncogene 15:2687-2698 (Pubitemid 27507616)
27. Yamada E, Yamazaki K, Takano K, Obara T, Sato K (2006) Iodide inhibits vascular endothelial growth factor-A expression in cultured human thyroid follicles: a microarray search for effects of thyrotropin and iodide on angiogenesis factors. Thyroid 16:545-554 (Pubitemid 44066261)
28. Jebreel A, England J, Bedford K, Murphy J, Karsai L, Atkin S (2007) Vascular endothelial growth factor (VEGF), VEGF receptors expression and microvascular density in benign and malignant thyroid diseases. Int J Exp Pathol 88:271-277 (Pubitemid 47256303)
29. Hoffmann S, Hofbauer LC, Scharrenbach V, Wunderlich A, Hassan I, Lingelbach S, Zielke A (2004) Thyrotropin (TSH)-induced production of vascular endothelial growth factor in thyroid cancer cells in vitro: evaluation of TSH signal transduction and of angiogenesis-stimulating growth factors. J Clin Endocrinol Metab 89:6139-6145 (Pubitemid 39628426)
30. Baffert F, Le T, Sennino B, Thurston G, Kuo CJ, Hu-Lowe D, McDonald DM (2006) Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Am J Physiol Heart Circ Physiol 290:H547-H559
31. Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR, Norberg SM, O'Brien SM, Davis RB, Gowen LC, Anderson KD, Thurston G, Joho S, Springer ML, Kuo CJ, McDonald DM (2006) VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 290:H560-H576
32. Salem AK, Fenton MS, Marion KM, Hershman JM (2008) Effect of sunitinib on growth and function of FRTL-5 thyroid cells. Thyroid 18:631-635 (Pubitemid 351918450)
33. Williams KJ, Telfer BA, Shannon AM, Babur M, Stratford IJ, Wedge SR (2007) Combining radiotherapy with AZD2171, a potent inhibitor of vascular endothelial growth factor signaling: pathophysiologic effects and therapeutic benefit. Mol Cancer Ther 6:599-606 (Pubitemid 46332462)
34. Alexandrescu DT, Popoveniuc G, Farzanmehr H, Dasanu CA, Dawson N, Wartofsky L (2008) Sunitinib-associated lymphocytic thyroiditis without circulating antithyroid antibodies. Thyroid 18:809-812 (Pubitemid 352009925)
35. Illouz F, Laboureau-Soares S, Dubois S, Rohmer V, Rodien P (2009) Tyrosine kinase inhibitors and modifications of thyroid function tests: a review. Eur J Endocrinol 160:331-336
36. Rivas M, Santisteban P (2003) TSH-activated signaling pathways in thyroid tumorigenesis. Mol Cell Endocrinol 213:31-45 (Pubitemid 38229153)
37. Calebiro D, de Filippis T, Lucchi S, Martinez F, Porazzi P, Trivellato R, Locati M, Beck-Peccoz P, Persani L (2006) Selective modulation of protein kinase A I and II reveals distinct roles in thyroid cell gene expression and growth. Mol Endocrinol 20:3196-3211 (Pubitemid 44833565)
38. Torino F, Corsello SM, Longo R, Barnabei A, Gasparini G (2009) Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol 6:219-228
39. Novartis Pharmaceuticals Corporation (2010) Gleevec (imatinib mesylate): full prescribing information. Novartis Pharmaceuticals Corporation, East Hanover
40. Shinohara N TM, Kamishima T, Ikushima H, Sazawa A, Kanayama H, Nonomura K (2009) Efficacy and thyroidal effects of sunitinib in Japanese patients with metastatic renal cell carcinoma: hypothyroidism and thyroid atrophy as potential biomarkers for sunitinib? J Clin Oncol 27 (suppl; abstr e16097)
41. Schmidinger M, Vogl UM, Bojic M, Lamm W, Heinzl H, Haitel A, Clodi M, Kramer G, Zielinski CC (2011) Hypothyroidism in patients with renal cell carcinoma: blessing or curse? Cancer 117:534-544
42. Riesenbeck LM, Bierer S, Hoffmeister I, Kopke T, Papavassilis P, Hertle L, Thielen B, Herrmann E (2010) Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib. World J Urol. doi:10.1007/s00345-010-0627-2
43. Garfield D, Hercbergs A, Davis P (2007) Unanswered questions regarding the management of sunitinib-induced hypothyroidism. Nat Clin Pract 4:674
44. Theodossiou C, Skrepnik N, Robert EG, Prasad C, Axelrad TW, Schapira DV, Hunt JD (1999) Propylthiouracil-induced hypothyroidism reduces xenograft tumor growth in athymic nude mice. Cancer 86:1596-1601 (Pubitemid 29489797)
45. Goodman AD, Hoekstra SJ, Marsh PS (1980) Effects of hypothyroidism on the induction and growth of mammary cancer induced by 7,12-dimethylbenz(a) anthracene in the rat. Cancer Res 40:2336-2342 (Pubitemid 10082247)
46. Cristofanilli M, Yamamura Y, Kau SW, Bevers T, Strom S, Patangan M, Hsu L, Krishnamurthy S, Theriault RL, Hortobagyi GN (2005) Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma. Cancer 103:1122-1128 (Pubitemid 40328081)
47. Hercbergs AA, Goyal LK, Suh JH, Lee S, Reddy CA, Cohen BH, Stevens GH, Reddy SK, Peereboom DM, Elson PJ, Gupta MK, Barnett GH (2003) Propylthiouracil-induced chemical hypothyroidism with high-dose tamoxifen prolongs survival in recurrent high grade glioma: a phase I/II study. Anticancer Res 23:617-626 (Pubitemid 36358462)
48. Nelson M, Hercbergs A, Rybicki L, Strome M (2006) Association between development of hypothyroidism and improved survival in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 132:1041-1046 (Pubitemid 44600780)
49. Gharib H, Tuttle RM, Baskin HJ, Fish LH, Singer PA, McDermott MT (2004) Subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and the Endocrine Society. Endocr Pract 10:497-501
50. Fatourechi V (2009) Subclinical hypothyroidism: an update for primary care physicians. Mayo Clin Proc 84:65-71
51. Feldman DR, Martorella AJ, Robbins RJ, Motzer RJ (2007) Re: hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Nat Cancer Inst 99:974-975, author reply 976-977 (Pubitemid 47073505)
52. Dedecjus M, Kolomecki K, Brzezinski J, Adamczewski Z, Tazbir J, Lewinski A (2007) Influence of L-thyroxine administration on poor-platelet plasma VEGF concentrations in patients with induced short-term hypothyroidism, monitored for thyroid carcinoma. Endocr J 54:63-69 (Pubitemid 46481673)
53. Bladou F GG, Sabatier R, Deville J, Walz J, Narbonne H, Marcy M, Salem N, Brunelle S, Eymard J (2010) Hypothyroidism and survival during sunitinib therapy in metastatic renal cell carcinoma (mRCC): a prospective observational analysis. J Clin Oncol 28 (suppl; abstr e15013)